02487.HK
Cutia Therapeutics
HKSE · Healthcare · Biotechnology · CN
HKD 0.69
−4.17%Year over year
Reported trailing growth
- Revenue
- +32.9%
- EBITDA
- +45.4%
- EBIT
- +41.5%
- EPS
- +48.0%
- Free cash flow
- +42.9%
- Operating cash flow
- +40.9%
Forward estimates
Based on analyst estimates
- Revenue
- -74.7%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +209.2%
- EBITDA
- +36.4%
- EBIT
- +32.2%
- Net income
- +21.6%
- EPS
- +27.0%
- Free cash flow
- +35.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026